Publications by authors named "David Azorsa"

Claim this Profile
I
Immunohistochemical detection of PAX-FOXO1 fusion proteins in alveolar rhabdomyosarcoma using breakpoint specific monoclonal antibodies.
David O Azorsa, Peter K Bode, Marco Wachtel, Adam Tai Chi Cheuk, Paul S Meltzer

Mod Pathol· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
In vitro activity of a G-quadruplex-stabilizing small molecule that synergizes with Navitoclax to induce cytotoxicity in acute myeloid leukemia cells.
Justin J Montoya, Megan A Turnidge, Daniel H Wai, Apurvi R Patel, David W Lee, David O Azorsa

BMC Cancer· December 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical resistance associated with a novel MAP2K1 mutation in a patient with Langerhans cell histiocytosis.
David O Azorsa, David W Lee, Daniel H Wai, Ranjan Bista, Apurvi R Patel

Pediatr Blood Cancer· September 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Optimization of Transfection Conditions for siRNA Screening.
Justin J Montoya, David O Azorsa

Methods Mol Biol· December 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Data Analysis for High-Throughput RNAi Screening.
David O Azorsa, Megan A Turnidge, Shilpi Arora

Methods Mol Biol· December 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Disulfiram overcomes bortezomib and cytarabine resistance in Down-syndrome-associated acute myeloid leukemia cells.
Ranjan Bista, David W Lee, Oliver B Pepper, David O Azorsa, Robert J Arceci

J Exp Clin Cancer Res· February 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Aurora B kinase is a potent and selective target in MYCN-driven neuroblastoma.
Dominik Bogen, Jun S Wei, David O Azorsa, Pinar Ormanoglu, Eugen Buehler

Oncotarget· November 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
High-throughput RNAi screening for the identification of novel targets.
Meredith C Henderson, David O Azorsa

Methods Mol Biol· August 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Negative regulation of NF-κB by the ING4 tumor suppressor in breast cancer.
Sara A Byron, Elizabeth Min, Tanya S Thal, Galen Hostetter, Aprill T Watanabe, David O Azorsa

PLoS One· May 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
BIRC5 expression is a poor prognostic marker in Ewing sarcoma.
Pooja Hingorani, Paul Dickman, Pamela Garcia-Filion, Andrea White-Collins, Edward A Kolb, David O Azorsa

Pediatr Blood Cancer· January 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Foxo3a drives proliferation in anaplastic thyroid carcinoma through transcriptional regulation of cyclin A1: a paradigm shift that impacts current therapeutic strategies.
Laura A Marlow, Christina A von Roemeling, Simon J Cooper, Yilin Zhang, Stephen D Rohl, David O Azorsa

J Cell Sci· September 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The genomic and proteomic content of cancer cell-derived exosomes.
Meredith C Henderson, David O Azorsa

Front Oncol· August 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
RNAi screening of the kinome with cytarabine in leukemias.
Raoul Tibes, James M Bogenberger, Leena Chaudhuri, R Tanner Hagelstrom, Donald Chow, David O Azorsa

Blood· March 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
High-throughput RNAi screening identifies a role for TNK1 in growth and survival of pancreatic cancer cells.
Meredith C Henderson, Irma M Gonzales, Shilpi Arora, Ashish Choudhary, Jeffrey M Trent, David O Azorsa

Mol Cancer Res· June 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
RNAi-based functional pharmacogenomics.
Sukru Tuzmen, Pinar Tuzmen, Shilpi Arora, Spyro Mousses, David Azorsa

Methods Mol Biol· April 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
NCI60 cancer cell line panel data and RNAi analysis help identify EAF2 as a modulator of simvastatin and lovastatin response in HCT-116 cells.
Sevtap Savas, David O Azorsa, Hamdi Jarjanazi, Irada Ibrahim-Zada, Irma M Gonzales

PLoS One· April 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Amplification and overexpression of vinculin are associated with increased tumour cell proliferation and progression in advanced prostate cancer.
Christian Ruiz, David R Holz, Martin Oeggerli, Sandra Schneider, Irma M Gonzales, David O Azorsa

J Pathol· March 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Detailed molecular fingerprinting of four new anaplastic thyroid carcinoma cell lines and their use for verification of RhoB as a molecular therapeutic target.
Laura A Marlow, Jaclyn D'Innocenzi, Yilin Zhang, Stephen D Rohl, Simon J Cooper, David O Azorsa

J Clin Endocrinol Metab· December 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
RNAi screening of the kinome identifies modulators of cisplatin response in ovarian cancer cells.
Shilpi Arora, Kristen M Bisanz, Lourdes A Peralta, Gargi D Basu, Ashish Choudhary, David O Azorsa

Gynecol Oncol· September 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Genome-wide identification of PAX3-FKHR binding sites in rhabdomyosarcoma reveals candidate target genes important for development and cancer.
Liang Cao, Yunkai Yu, Sven Bilke, Robert L Walker, Linnia H Mayeenuddin, David O Azorsa

Cancer Res· August 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
RNAi phenotype profiling of kinases identifies potential therapeutic targets in Ewing's sarcoma.
Shilpi Arora, Irma M Gonzales, R Tanner Hagelstrom, Christian Beaudry, Ashish Choudhary, David O Azorsa

Mol Cancer· August 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A high-content RNAi-screening assay to identify modulators of cholesterol accumulation in Niemann-Pick type C cells.
Shilpi Arora, Christian Beaudry, Kristen M Bisanz, Chao Sima, Jeffrey A Kiefer, David O Azorsa

Assay Drug Dev Technol· June 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Chemogenomic analysis identifies Macbecin II as a compound specific for SMAD4-negative colon cancer cells.
Christine Kaiser, Nathalie Meurice, Irma M Gonzales, Shilpi Arora, Christian Beaudry, David O Azorsa

Chem Biol Drug Des· April 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
K
Kinome-wide RNAi studies in human multiple myeloma identify vulnerable kinase targets, including a lymphoid-restricted kinase, GRK6.
Rodger E Tiedemann, Yuan Xiao Zhu, Jessica Schmidt, Hongwei Yin, Chang-Xin Shi, David Azorsa

Blood· February 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
High-content siRNA screening of the kinome identifies kinases involved in Alzheimer's disease-related tau hyperphosphorylation.
David O Azorsa, RiLee H Robeson, Danielle Frost, Bessie Meec hoovet, Gillian R Brautigam

BMC Genomics· January 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis